Aigen Investment Management LP Buys 7,188 Shares of Catalent, Inc. (NYSE:CTLT)

Aigen Investment Management LP grew its stake in Catalent, Inc. (NYSE:CTLTFree Report) by 129.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,736 shares of the company’s stock after purchasing an additional 7,188 shares during the quarter. Aigen Investment Management LP’s holdings in Catalent were worth $572,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Gladius Capital Management LP acquired a new stake in Catalent during the third quarter worth approximately $28,000. GAMMA Investing LLC bought a new stake in Catalent in the 4th quarter valued at $33,000. Cary Street Partners Investment Advisory LLC grew its holdings in Catalent by 1,162.3% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company’s stock valued at $35,000 after buying an additional 709 shares in the last quarter. Rakuten Securities Inc. bought a new position in Catalent during the 4th quarter worth $46,000. Finally, Federated Hermes Inc. acquired a new stake in shares of Catalent during the fourth quarter worth $46,000.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on CTLT. Royal Bank of Canada reiterated a “sector perform” rating and issued a $63.50 price objective on shares of Catalent in a research note on Tuesday, February 20th. Barclays increased their price objective on shares of Catalent from $45.00 to $47.00 and gave the stock an “equal weight” rating in a research note on Thursday, January 25th. StockNews.com initiated coverage on shares of Catalent in a report on Tuesday. They set a “sell” rating for the company. Stephens reissued an “equal weight” rating and issued a $63.50 price objective on shares of Catalent in a research note on Thursday, April 4th. Finally, UBS Group restated a “neutral” rating and set a $63.50 target price (up from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, Catalent presently has a consensus rating of “Hold” and an average price target of $53.14.

Read Our Latest Stock Report on CTLT

Catalent Stock Performance

Shares of Catalent stock opened at $54.89 on Thursday. Catalent, Inc. has a twelve month low of $31.80 and a twelve month high of $60.20. The company’s fifty day moving average is $56.09 and its 200 day moving average is $50.55. The company has a debt-to-equity ratio of 1.37, a current ratio of 2.51 and a quick ratio of 1.77.

Catalent (NYSE:CTLTGet Free Report) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.36). The company had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.11 billion. Catalent had a negative net margin of 26.61% and a negative return on equity of 2.73%. On average, sell-side analysts predict that Catalent, Inc. will post 0.28 earnings per share for the current fiscal year.

About Catalent

(Free Report)

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.

Recommended Stories

Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent, Inc. (NYSE:CTLTFree Report).

Institutional Ownership by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.